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SUMMARY 
Platelet MAO activity of 30 male drug free chronic schizophrenics (RDC), 30 male first degree relative 
of these patients and31 age matched male healthy controls was studied. Analysis of variance revealed that no signi-
ficant differences existed between the three groups. There was high correlation between the enzyme activily of pro-
bands and first degree relatives. Presence or absence of auditory nallucinations, or paranoid features did not affect 
the enzyme activity significantly. 
Introduction 
Monoamine oxidase (MAO), an inso-
luble mitochondrial enzyme, metabolises a 
number of biologically active monoamines 
most of which are known neurotransmit-
ters or neurotransmitter candidates. It has 
been implicated in the causation of various 
neuropsychiatric illnesses. A positive corre-
lation between brain and platelet MAO ac-
tivity has been observed by Robinson and 
associates in 1971. Easier accessibility to 
platelet MAO as compared to brain MAO 
has resulted in a number of studies of pla-
telet MAO activity in order to explain pa-
thophysiology of various neuropsychiatric 
illnesses. Murphy and Wyatt (1972) have 
observed a decreased platelet MAO activity 
in chronic schizophrenic psychosis and sug-
gested that platelet MAO activity can serve 
as a biological marker for schizophrenia. 
Since then 42 studies have been reported in 
world literature. 26 of these have replicated 
the above findings, while others have not, 
issue is still controversial. In order to study 
this important biological variable in Indian 
patients, we carried out this work with the 
following aims: 
1. To study platelet monoamine oxidase 
(MAO) activity in a group of chronic 
schizophrenia and matched controls. 
2. To study platelet MAO activity in first 
degree relatives of patients of chronic 
schizophrenia. 
Material and Methods 
A. Patient Sample: 30 patients suffering 
from chronic schizophrenic psychosis were 
included in the study according to follow-
ing inclusion and exclusion creiteria -
Inclusion Criteria — 
(a) RDC diagnosis of chronic schizoph-
renic psychosis (Spitzer et al 1978). 
(b) 17 to 60 years of age. 
(c) Male sex 
(d) Resident of Lucknow 
Exclusion Criteria — 
(a) History of neuroleptic intake within 
past one week 
(b) Presence of anaemia (Hb< 10Gm%) 
(c) Evidence of organic brain syndrome 
(d) History of alcohol abuse or any other 
drug abuse (e.g. cannabis, marijuhana, 
opium) within past 6 months. 
(e) Non-availability of required male first 
degree relative. 
(f) Absence of consent 
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B. Control: 31 age matched male healthy 
volunteers were selected as controls from 
amongst the non-professional hospital staff 
and relatives of surgical patients. Following 
exclusion criteria were strictly observed — 
(a) Hb<10 Gm% 
(b) History of Neuro-psychiatric illness 
(migraine, Huntington's chorea, schi-
zophrenic psychosis, affective disor-
der) in the subject himself or his first 
degree relatives. 
(c) Presence of physical illness requiring 
medication. 
(d) History of alcohol abuse or any other 
drug addiction (Cannabis, marijuana, 
opium) within past 6 months. 
(e) First degree relatives: One male first 
degree relatives for each selected by 
random sampling was taken up for esti-
mation of platelet MAO activity. 
All patients attending psychiatry out-
patients department at G.M. and Associated 
Hospitals, Lucknow were screened for inc-
lusion in the study. First 30 patients fulfil-
ling the inclusion-exclusion criteria were 
hospitalised and kept drug free. They were 
examined independently by two psychia-
trists to ensure the diagnosis. First degree 
relative included in the study was also exa-
mined for the presence of any physical or 
psychiatric illness. All data were recorded 
,on a semi-structured proforma. Blood 
samples were collected on the day of hospi-
talisation in the morning between 10.00 
A.M. and 12.00 noon after the clinical exa-
mination was completed. 
17ml. of venous blood was collected 
through vene-puncture into plastic syringes 
(steriware) rinsed with acid citrate dextrose 
solution, and was then transferred imme-
diately into two polypropylene tubes each 
containing 1.5 ml. of acid citrate dextrose 
(ACD) solution. The tubes were immidia-
tely placed in ice. Platelet rich plasma 
(PPvP) was prepared within 4 hours by dif-
ferential refrigerated centrifugation at 4°C. 
Centrifugations were done at 175g., 300g. 
and 600g. for 10 minutes each and PRP ob-
tained after each centrifugation was pooled 
(Sullivan et al ,1977). Platelet counts were 
done in PRP using light microscope and 
Neubauer's chamber. PRP was stored at — 
70
CC till the time of assay, but never more 
than 2 weeks (No sufficient change in en-
zyme activity occurs at this temperature for 
6 weeks, Murphy et al 1976). At the time of 
assay PRP was thawed. Platelet pellets were 
obtained by centrifuging PRP at 3000g. for 
10 minutes in a refrigerated centrifuge. Pel-
lets were washed with normal saline and 
then sonicated with 0.1 ml distilled water 
for each ml of PRP and were separated into 
alliquots of 0.2 ml. Platelet MAO activity 
was estimated in these alliquots using ben-
zylamine as substrate by spectro-photo-me-
teric method of Tabor et al (1955). Proteins 
were estimated in these alliquots by me-
thod of Lowry et al (1951). Estimaters were 
blind to the identity of the sample. All the 
estimations were done at Industrial Toxico-
logy Research Centre. All the samples were 
run in duplicate. Samples from patients and 
corresponding first degree relatives and 
controls were obtained on the same day and 
their estimations done the same day. En-
zyme activity was calculated in terms of n 
moles of benzaldehyde formed per 10
8 pla-
telets per hour and also n moles of benzal-
dehyde formed per mg of platelet protein 
per hour. Statistical analysis was done using 
one way analysis of variance. 
Results 
Sample Characteristics: 
We studied 30 male patients of chronic 
schizophrenia (RDC) with an average age 
of 30.03 (±6.86) years, age of onset of ill-
ness 23.03 (±7.53) years and average dura-
tion of illness 7.17 (±4.43) years (Table 1). 
Controls were 31 males with an average A. K. GUPTA ET AL  281 
Table 1 
Sample Characteristics 
AGE (in years) 
Mean 
S.D. 
Range 
Hb (Gm%) 
Mean 
S.D. 
Range 
Platelet Count 
x lO'/cc of PRP 
Mean 
S.D. 
Range 
Patients 
(N = 30) 
30.03 
6.86 
19^5 
11.45 
1.01 
10.0-14.0 
2.54 
1.10 
1.0-4.26 
1st Relatives 
(N = 30) 
41.43 
18.57 
19-71 
11.57 
0.99 
10.0-14.0 
3.06 
1.69 
1.11-8.41 
Controls 
(N = 30) 
30.39 
7.39 
18-46 
11.72 
1.29 
10.0-14.5 
2.81 
1.55 
0.88-5.77 
age 30.39 (± 7.30) years. First degree rela-
tives were 30 males with an average age 
41.43 (±18.57) years with a range of 19 to 
71 years, 3 of them were sons, 12 were fath-
ers and 15 were brothers. The mean hae-
moglobin was 11.45 gm% for first degree 
relatives. Platelet counts were 2.54 x 10
8 
per cc of PRP for patients, 3.06 x 10
8 per cc 
of PRP for first degree relatives and 2.81 x 
10
8 per cc PRP for controls. We were un-
able to observe any enzyme activity in pla-
telets of 4 patients, 4 first degree relatives 
and one control because their enzyme ac-
tivity was so low that it could not be detect-
ed by our method of estimation. These sub-
jects were excluded from further statistical 
analysis. 
Table 2 
Platelet MAO Activity in Patients, First 
Degree Relatives and Controls 
Patients 1st Relatives Controls 
(N = 26) (N = 26) (N = 30) 
n Moles/10
8 
Platelets/hr. 
Mean 
S.D. 
24.15 
25.07 
24.77 
21.27 
30.25 
28.56 
F 2.81=0.003, N.S. 
n Moles/mg 
Platelets 
protein/hr. 
Mean 
S.D. 
43.78 60.82 59.62 
43.28 63.75 69.95 
F 2.79 = 0.45, N.S. 
The platelet MAO activity did not dif-
fer significantly between the three groups 
i.e. patients did not differ from controls or 
first degree relatives, and first degree rela-
tives did not differ from controls. 
Table 3 
Correlation Coefficient Between Platelet 
MAO Activity and other Variables 
1. Correlating between two values of platelet MAO 
activity (r) = 0.81, (p<.001) 
2. Correlation between platelet MAO activity of 
patients and 1st relatives (r) = 0.56, (p<.0l) 
3. Correlation between age of onset of illness and 
platelet MAO activity (r) = -0.14 (NS.) 
4. Correlation between duration of illness and 
platelet MAO. activity (r) = -0.17 (N.S.) 
There is a highly significant correlation 
(r = 0.81, p<.001) between two values of 
platelet MAO activity for the whole group. 
There was a significant correlation (r = 
0.56, p<.01) between the platelet MAO ac-
tivity of patients and their first degree rela-
tives. However no correlation was seen bet-
ween platlet MAO activity and either the age 
of onset of illness or the duration of illness. 
Table 4 
Comparison beween treated and untreated 
patients and MAO values 
Treated Untreated 
Patients Patients 
(N = 5) (N = 21) 
Control 
(N = 30) 
n Moles/10
8 
Platelets/hr. 
Mean 
S.D. 
9.17 27.72 30.25 
12.05 26.03 28.56 
F 2.55 = 1.28, N.S. 
n Moles/mg. 
platelet 
protein/hr. 
Mean 
S.D. 
10.59 51.71 59.62 
6.75 44.51 69.95 
F 2.53 = 1.45, N.S. 
In order to exclude the effect of neuro 
leptic treatment on platelet MAO activity 
the sample was divided into two groups. 
There were only 5 patients who presented 
with a history of neuroleptic treatment for 
a variable period of two months to ten years 
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for eight days, one for twenty five days and 
one for one and a half years prior to inclu-
sion in the study. Twenty one patients had 
not received any treatment with neurolept-
ic drugs in the past. Treated groups of pa-
tients tended to have lower values of plate-
let MAO activity as compared to untreated 
group of patients and controls. But this dif-
ference failed to reach any statistical signi-
ficance. 
Table 5 
ANOVA of platelet MAO activity according 
to presence or absence of hallucinations 
Patients with Patients with-
Auditory out Auditory Control 
hallucina- hallucinations (N = 30) 
tions(N = 17) (N = 9) 
n motes/10
8 
Platelets/hr 
Mean 
S.D. 
26.42 21.65 
25.68 22.28 
F 2,55 = 0.41, N.S. 
30.25 
28.56 
n moles/mg. 
Platelet 
Protein/hr 
Mean 
S.D. 
46.05 39.55 59.62 
45.95 37.30 69.95 
= 2, 53=0.51, N.S. 
The sample was divided into two groups 
according to presence or absence of audito-
ry hallucinations. There were 17 patients 
who presented with auditory hallucina-
tions at the time of inclusion in the study or 
later during hospitalization. 9 patients did 
not have any auditory hallucinations at any 
time. The two groups did not differ signi-
ficantly, nor were any differences observed 
from controls. 
Two groups were formed - Chronic Pa-
ranoid (CP) schizophrenia (N = ll) and 
chronic undifferentiated schizophrenia 
(CU) (N = 15) according to RDC (Spitzer 
et al 1978). There are no significant diffe-
rences in the platelet MAO activity bet-
ween the two groups and controls and 
among themselves. 
The sample was then looked at by cate-
gorising it into paranoid and non-paranoid 
Table 6 
Comparison between subgroups of schizo-
phrenia (According to RDC, Spitzer et al 
1978) on MAO values 
Chronic Chronic 
paranoid Undifferen-
(N = ll) 
tiated 
(N-15) 
Control 
(N = 30) 
n Moles/10' 
Platelets/hr 
Mean 
S.D. 
32.61 17.95 30.25 
32.40 15.12 28.56 
F 2.55 = 1.26, N.S. 
n moles/mg 
platelet 
protein/hr 
Mean 
S.D. 
54.49 35.96 59.62 
46.95 39.50 69.95 
F 2.53 =0.48, N.S. 
Table 7 
Comparison of MAO values according to 
subgroups of schizophrenia (Potkin etaI1978) 
n Moles/10' 
platelets/hr 
Mean 
S.D. 
Paranoid Non-paranoid Controls 
(N = 19) (N = 7) (N = 30) 
28.74 12.83 30.25 
27.28 11.21 28.56 
F 2.55 = 1.18, N.S. 
n Moles/mg 
platelet 
protein/hr 
Mean 55.46 12.14 59.62 
S.D. 45.19 6.68 69.95 
F 2.53 = 1.87, N.S. 
groups according to criteria described by 
Potkin and associates (1978). According to 
these criteria paranoid group includes pa-
tients of CP Schizophrenia (RDC) and CU 
schizophrenia (RDC) with secondary para-
noid features of suspiciousness, preoccupa-
tion with and systematization of delu-
sions, delusions of control, stereotyped be-
haviour, intact memory, rigidity of ideas 
and communication characterised by evasi-
veness and misleading- responses. There 
were 19 patients in paranoid group and 7 
patients in non-paranoid group. Patients in 
non-paranoid group tended to have lower A. K. GUPTA ET AL  283 
values as compared to paranoid group as 
well as controls but this difference was not 
statistically significant. 
DISCUSSION 
We observed no significant difference 
in platelet MAO activity between patient 
and control groups. These observations are 
in confirmity with observations of 16 previ-
ous studies (Shaskan and Becker, 1975, 
Brockington et al 1976, Schildkraut et al 
1976, White et al 1976, Belmaker et al 
1976, Belmaker et al 1977, Sullivan et al 
1977, Demisch et al 1977, Groshong et al 
1978, Friedhoff et al 1978, Landowski, 
1977, Banki, 1978, Mann and Thomas, 
1979, Meltzer et al 1980, Ho et al 1982, 
Karson et al 1983). Of the 26 studies ob-
serving significant reduction of platelet 
MAO activity in chronic schizophrenics as 
compared to controls 6 have been conduct-
ed at the same laboratory (Murphy and 
Wyatt, 1972, Wyatt et al 1973, Murphy et 
al, 1974, Berget et al 1978, Wyatt et al 
1978, Potkin et al 1978) and have been 
published more than once. Discrepancy in 
literature on the subject has arisen probably 
because of lack of control of several va-
riables namely sex, heterogenous diagnost-
ic criteria, neuroleptic treatment, presence 
of anaemia and use of different substrates. 
Most of these have been done on chronic 
institutionalised patients being treated with 
neuroleptic drugs over a prolonged period. 
Well defined diagnostic criteria have been 
used in only few of them. Studies with wo-
men have not been controlled for their 
menstrual cycle. Presence of anaemia has 
not been looked into in most of them, ex-
cept two (Barrettini et al 1978, Brockington 
et al 1976). Brockington and associates 
(1976) excluded anaemic subjects and did 
not observe any significant difference in 
platelet MAO activity between patients 
and controls. Murphy and co-workers 
(1982) have stated that neuroleptic trea-
tement does not seem to influence platelet 
MAO activity but their observations were 
based on repeat estimations after a small 
drug free period of only 2 weeks on chroni-
cally treated patients. Prospective studies 
on the subject have strongly suggested a 
contribution of neuroleptic drugs in reduc-
ing platelet MAO activity of schizophrenic 
patients treated for a long time (Becker and 
Shaskan, 1977, Owen et al 1981, Meltzer et 
al 1980, Friedhoff et al 1978, Ho et al 1982). 
• The only Indian study on the subject 
published till date (Sengupta et al 1981) 
was also conducted on a small group of 
chronic schizophrenics (N = 14) most of 
whom were being treated with neuroleptic 
drugs, and females were not controlled for 
period of menstural cycle. They have also 
used the spectrophotometric method of en-
zyme estimation because radioactive la-
belled substrates are not available in India at 
present. 
We have controlled all of these va-
riables by selecting patients by well defined 
criteria (RDC, Spitzer et al 1978), taking up 
only males, including fairly age matched 
controls, excluding presence of anaemia, 
and excluding drug abuse. 21 out of our 26 
patients had not received any neuroleptic 
treatment. 5 treated patients tended to have 
lower platelet MAO activity as compared 
to untreated group as well as controls, 
though this difference did not achieve sta-
tistical significance. The wide range of va-
lues observed in our sample is in harmony 
with observations reported in some other 
studies (Brockingtoner al 1976, Friedhoff et 
al 1978, Mann and Thomas, 1979 ; Ho et al, 
1982; Belmaker et al 1977) though varia-
tions are much wider in our sample. It could 
be so because our sample was not con-
trolled for diet. Blood glucose levels have 
been observed to be correlated with plate-
let MAO activity (Demisch et al 1979). 
Ideal would have been to keep the patients 
fasting, but it was difficult in our set-up to 
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adequate period of time. Another possibil-
ity is the effect of wide variations in envi-
ronmental temperature. Though samples 
were always carried and processed in ice, 
there are still chances of artefacts creeping 
in because of this. Parellel running of 
samples from patients and controls should . 
have countered this artefact. 
Studies of brain monoamine oxidase ac-
tivity done on chronic schizophrenic pati-
ents post-mortem (Reveley et al 1981, 
Utena et al 1968, Vogal et al 1969, Do-
mino et al 1973, Nies et al 1974, Schwartz 
et al 1974, Crowe et al 1978) have not re-
ported any significant difference between 
chronic schizophrenics and controls. These 
studies also support our observations. 
Yet another possiblility responsible for 
non-conformity of literature on the subject 
is a presence of biological heterogeneity 
within the schizophrenia group and may be 
there is a small yet unidentified sub-group 
of patients that have low platelet MAO ac-
tivity. Still more investigations are required 
with better control for several variables as 
delineated above to identfy this subgroup if 
it exists. Jeste and associates (1982) have 
suggested that probably paranoid group of 
patients form such a sub-group but our ob-
servations do not support their observa-
tions. 
Studies with monozygotic and dizygot-
ic twins (Nies et al 1973) and families of 
chronic schizophrenics (Berrettini et al 
1980) have suggested that probably platelet 
MAO activity is genetically controlled and 
may serve as a genetic marker for vulnera-
bility to chronic schizophrenia. We at-
tempted to study this aspect using single 
sibling paradigm as suggested by Reider 
and Gershon (1978). Though we observe a 
significant correlation between platelet 
MAO activity of patients and their male 
first degree relatives, the importance of this 
observation is nullified by the absence of 
any significantly lowered platelet MAO 
activity in the patient group which is a pre-
requisite before the single sibling paradigm 
of Reider and Gershon (1978) can be ap-
plied. 
Conclusions 
There is no significant difference in pla-
telet MAO activity between schizophren-
ics and healthy controls. 
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